|Name:||Selection and case-control matching for COVID-19 re-imaging|
The COVID-19 re-imaging study was set up to investigate the potential effects of SARS-CoV-2 infection on internal organs by comparing imaging scans taken from participants both before and after infection. Between 2014 and 2021, approximately 49,000 UK Biobank participants had attended an imaging assessment in one of four UK Biobank centres, based in Cheadle (Stockport), Newcastle, Reading and Bristol. About 3,200 participants had also attended a repeat imaging visit.
The pandemic forced a temporary closure of all imaging clinics, but in February 2021 they re-opened to perform repeat scans for the purposes of COVID-19 research. The study aims to invite up to 3,000 of the 49,000 participants who had previously attended an imaging assessment for a repeat assessment. Half of the participants will have been previously infected with SARS-COV-2 (designated as 'cases') and half will not ('controls'). Identification of previous infection is based on data from linked antigen (swab) test or clinical code data and home-based lateral flow antibody tests sent to participants.
This document describes the eligibility criteria for this study, including the details of the case-control matching.
This resource is not suitable for displaying within a web-browser.
It can be downloaded or viewed using the link: casecontrol_covidimaging.pdf
If you have wget available (typically on linux systems), then you can also obtain a copy using the command
wget -nd biobank.ndph.ox.ac.uk/ukb/ukb/docs/casecontrol_covidimaging.pdf